165 related articles for article (PubMed ID: 30514181)
21. ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.
Li M; Seiser EL; Baldwin RM; Ramirez J; Ratain MJ; Innocenti F; Kroetz DL
Pharmacogenomics J; 2018 Jan; 18(1):35-42. PubMed ID: 27845419
[TBL] [Abstract][Full Text] [Related]
22. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.
Jada SR; Lim R; Wong CI; Shu X; Lee SC; Zhou Q; Goh BC; Chowbay B
Cancer Sci; 2007 Sep; 98(9):1461-7. PubMed ID: 17627617
[TBL] [Abstract][Full Text] [Related]
23. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
Massacesi C; Terrazzino S; Marcucci F; Rocchi MB; Lippe P; Bisonni R; Lombardo M; Pilone A; Mattioli R; Leon A
Cancer; 2006 Mar; 106(5):1007-16. PubMed ID: 16456808
[TBL] [Abstract][Full Text] [Related]
24. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.
de Man FM; Goey AKL; van Schaik RHN; Mathijssen RHJ; Bins S
Clin Pharmacokinet; 2018 Oct; 57(10):1229-1254. PubMed ID: 29520731
[TBL] [Abstract][Full Text] [Related]
25. Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on Irinotecan Induced Side Effects.
Toshimoto K; Tomaru A; Hosokawa M; Sugiyama Y
Pharm Res; 2017 Aug; 34(8):1584-1600. PubMed ID: 28397089
[TBL] [Abstract][Full Text] [Related]
26. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question.
Deeken JF; Slack R; Marshall JL
Cancer; 2008 Oct; 113(7):1502-10. PubMed ID: 18720361
[TBL] [Abstract][Full Text] [Related]
27. Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.
Inoue K; Sonobe M; Kawamura Y; Etoh T; Takagi M; Matsumura T; Kikuyama M; Kimura M; Minami S; Utsuki H; Yamazaki T; Suzuki T; Tsuji D; Hayashi H; Itoh K
Tohoku J Exp Med; 2013 Feb; 229(2):107-14. PubMed ID: 23303296
[TBL] [Abstract][Full Text] [Related]
28. [The risk of adverse events of CPT- 11].
Imataka H; Sekikawa T; Ichikawa W
Nihon Rinsho; 2016 Nov; 74(11):1847-1851. PubMed ID: 30550693
[TBL] [Abstract][Full Text] [Related]
29. Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
Tejpar S; Yan P; Piessevaux H; Dietrich D; Brauchli P; Klingbiel D; Fiocca R; Delorenzi M; Bosman F; Roth AD
Eur J Cancer; 2018 Aug; 99():66-77. PubMed ID: 29909091
[TBL] [Abstract][Full Text] [Related]
30. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.
Côté JF; Kirzin S; Kramar A; Mosnier JF; Diebold MD; Soubeyran I; Thirouard AS; Selves J; Laurent-Puig P; Ychou M
Clin Cancer Res; 2007 Jun; 13(11):3269-75. PubMed ID: 17510208
[TBL] [Abstract][Full Text] [Related]
31. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
Cecchin E; De Mattia E; Ecca F; Toffoli G
Drug Resist Updat; 2018 Jul; 39():18-40. PubMed ID: 30075835
[TBL] [Abstract][Full Text] [Related]
32. Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer.
Fujii H; Yamada Y; Watanabe D; Matsuhashi N; Takahashi T; Yoshida K; Suzuki A
Cancer Chemother Pharmacol; 2019 Jan; 83(1):123-129. PubMed ID: 30377777
[TBL] [Abstract][Full Text] [Related]
33. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
Fakih MG; Ross ME; Starostik P
Clin Colorectal Cancer; 2007 Jul; 6(8):583-7. PubMed ID: 17681105
[TBL] [Abstract][Full Text] [Related]
34. An overview of the recent progress in irinotecan pharmacogenetics.
Fujiwara Y; Minami H
Pharmacogenomics; 2010 Mar; 11(3):391-406. PubMed ID: 20235794
[TBL] [Abstract][Full Text] [Related]
35. [UGT1A1 Genotyping for Proper Use of Irinotecan].
Matsuoka A; Ando Y
Rinsho Byori; 2015 Jul; 63(7):876-82. PubMed ID: 26591441
[TBL] [Abstract][Full Text] [Related]
36. Role of pharmacogenetics in irinotecan therapy.
de Jong FA; de Jonge MJ; Verweij J; Mathijssen RH
Cancer Lett; 2006 Mar; 234(1):90-106. PubMed ID: 16343744
[TBL] [Abstract][Full Text] [Related]
37. [Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer].
Sun ZW; Wang XC; Gao J; Li J; Li YY; Dang YZ; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jun; 16(6):524-8. PubMed ID: 23801203
[TBL] [Abstract][Full Text] [Related]
38. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Carlini LE; Meropol NJ; Bever J; Andria ML; Hill T; Gold P; Rogatko A; Wang H; Blanchard RL
Clin Cancer Res; 2005 Feb; 11(3):1226-36. PubMed ID: 15709193
[TBL] [Abstract][Full Text] [Related]
39. Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time.
Hulshof EC; Deenen MJ; Guchelaar HJ; Gelderblom H
Eur J Cancer; 2020 Dec; 141():9-20. PubMed ID: 33125947
[TBL] [Abstract][Full Text] [Related]
40. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
de Jong FA; Kehrer DF; Mathijssen RH; Creemers GJ; de Bruijn P; van Schaik RH; Planting AS; van der Gaast A; Eskens FA; Janssen JT; Ruit JB; Verweij J; Sparreboom A; de Jonge MJ
Oncologist; 2006 Sep; 11(8):944-54. PubMed ID: 16951398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
